Influenza A virus neuraminidase (H5N1) (NA)

Influenza A neuraminidase (NA) is a critical surface glycoprotein found on the influenza virus envelope, specifically the N1 subtype associated with the highly pathogenic H5N1 strain (A/Vietnam/1203/2004). As an exo-alpha-sialidase, its primary biological function is to catalyze the hydrolysis of terminal sialic acid residues from host cell receptors and nascent viral particles. This enzymatic activity is essential for the release of progeny virions from infected cells and prevents the aggregation of viruses, allowing them to spread through the respiratory tract. In the context of H5N1, this protein is a major determinant of virulence and a primary target for antiviral therapy. Drugs such as oseltamivir and zanamivir function by binding to the highly conserved active site of the neuraminidase enzyme, thereby inhibiting viral replication. However, the high mutation rate of the influenza virus, particularly in the H5N1 lineage, poses a constant challenge due to the development of drug resistance, necessitating ongoing surveillance and the development of next-generation inhibitors.

Other names

NeuraminidaseSialidaseExo-alpha-sialidaseN1 neuraminidaseNA protein

Neuraminidase inhibitors competitively bind to the active site of the enzyme, preventing the cleavage of terminal sialic acid residues from host cell receptors and viral glycoproteins. This action traps newly formed virions on the surface of the infected cell and within the respiratory mucus, effectively halting the spread of the infection to neighboring cells.